하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.
하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
Hironic Inc. (CEO Jinwoo Lee), a leading aesthetic medical device company, announced on the 24th that it has signed new export contracts with distributors in Singapore and Malaysia. This comes just two weeks after securing a major KRW 48.4 billion (approx. USD 35.5 million) supply agreement for its SYNERJET device in the North American market.
According to a company official, “We recently signed agreements with key Asian distributors to export our flagship devices, including NEW DOUBLO 2.0 and SYNERJET. We aim to diversify our sales channels throughout Asia and increase our export ratio.”
Hironic is actively expanding its supply chain to accelerate sales recovery in Asia. The company has completed construction of its second and third manufacturing plants in Osong, Chungbuk Province, enhancing its production infrastructure. This expansion is expected to improve manufacturing efficiency and ensure a stable global supply to meet rising overseas demand. The company also aims to facilitate the resumption of stock trading by demonstrating robust operational capabilities.
SYNERJET, Hironic’s core product, utilizes a combination of Microjetting, Plasma, and Electroporation technologies to deliver skin booster ingredients without the use of needles. It offers the advantage of reduced pain and minimal downtime, making it highly attractive in both Asian and Western aesthetic markets.
Previously, on November 10, Hironic signed a conditional supply agreement with a North American medical device distributor worth KRW 48.4 billion, approximately 1.5 times the company’s 2024 annual revenue of KRW 31.6 billion. The contract runs through October 2030 and is contingent upon obtaining U.S. FDA and Canada MDEL approvals. The company anticipates FDA clearance in the first half of next year. Under the agreement, 50% of the payment is made at the time of order, with the remaining 50% prior to shipment.
Hironic is now at a pivotal point in its global expansion, driven by strategic partnerships across Asia and North America. Key challenges ahead include timely regulatory approvals, activation of local sales networks, and brand-building efforts in new international markets.
